Zacks Investment Research Lowers Leap Therapeutics (LPTX) to Hold

Leap Therapeutics (NASDAQ:LPTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “

Shares of Leap Therapeutics (NASDAQ LPTX) opened at $6.22 on Friday. The firm has a market cap of $75.73 and a price-to-earnings ratio of -1.80. Leap Therapeutics has a one year low of $4.90 and a one year high of $10.10.

Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.11). equities analysts expect that Leap Therapeutics will post -3.63 earnings per share for the current year.

In related news, COO Augustine Lawlor acquired 1,057,769 shares of the stock in a transaction dated Tuesday, November 14th. The stock was bought at an average price of $6.09 per share, for a total transaction of $6,441,813.21. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 58.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Lowers Leap Therapeutics (LPTX) to Hold” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/12/zacks-investment-research-lowers-leap-therapeutics-lptx-to-hold.html.

About Leap Therapeutics

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply